InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Geffken Daniel E., Chief Financial Officer. Director active across 2 companies, notably Eloxx Pharmaceuticals, Inc.. Aggregated, 3 reports have been recorded. Total volume traded: €64k. The latest transaction was filed on 7 June 2022 — Attribution. Regulator: SEC (Form 4). All data is openly available.
Declarations3 total
05,000 shares0
Common Stock
SEC:0001437749-22-014714:0·
€31,87850,000 shares@ €0.6376100.0% of flow
Common Stock
SEC:0001415889-21-005600·
Ideal exit: 26 Aug 2022 (T+270)
€31,87850,000 shares@ €0.637650.0% of flow
Common Stock
SEC:0001415889-21-005600:0·
Ideal exit: 26 Aug 2022 (T+270)
3 of 3 declarations
About Geffken Daniel E.
Daniel E. Geffken is the Interim Chief Financial Officer and Board Member at Eloxx Pharmaceuticals, Inc. and Windtree Therapeutics Inc. /DE/. He oversees the financial operations of both companies and is responsible for financial planning and risk management. His expertise is crucial in ensuring the financial health of these organizations.
